EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management

Maria Terrin, Giulia Migliorisi, Arianna Dal Buono iD, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi iD

International Journal of Molecular Sciences · 15.07.2023 · 24 (14) · 11504

DOI: 10.3390/ijms241411504 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.07.2023. Verfasst von Maria Terrin und 8 weiteren Autor:innen. Beteiligte Einrichtung: IBD Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. Hauptthemen laut MEDLINE: Colitis, Inflammatory Bowel Diseases, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the treatment of solid tumors has deeply transformed therapeutic algorithms in medical oncology. Approximately one-third of patients treated with ICIs may de velop immune-related adverse events, and the gastrointestinal tract is often affected by different grades of mucosal inflammation. Checkpoint inhibitors colitis (CIC) presents with watery or bloody diarrhea and, in the case of severe symptoms, requires ICIs discontinuation. The pathogenesis of CIC is multifactorial and still partially unknown: anti-tumor activity that collaterally effects the colonic tissue and the upregulation of specific systemic inflammatory pathways (i.e., CD8+ cytotoxic and CD4+ T lymphocytes) are mainly involved. Many questions remain regarding treatment timing and options, and biological treatment, especially with anti-TNF alpha, can be offered to these patients with the aim of rapidly resuming oncological therapies. CIC shares similar pathogenesis and aspects with inflammatory bowel disease (IBD) and the use of ICI in IBD patients is under evaluation. This review aims to summarize the pathogenetic mechanism underlying CIC and to discuss the current evidenced-based management options, including the role of biological therapy, emphasizing the relevant clinical impact on CIC and the need for prompt recognition and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisInflammatory Bowel DiseasesNeoplasmsHumansTumor Necrosis Factor Inhibitors

Stichwörter der Autor:innen

checkpoint inhibitorscolitisdiarrheaenterocolitisimmune-related adverse events

Substanzen

Tumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • IBD Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
  • Division of Gastroenterology and Digestive Endoscopy, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Medical Oncology and Haematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.

ORCID-Profile: Arianna Dal Buono, Alessandro Armuzzi

Zitieren

APA

Terrin, M., Migliorisi, G., Dal Buono, A., Gabbiadini, R., Mastrorocco, E., Quadarella, A., Repici, A., Santoro, A., & Armuzzi, A. (2023). Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences, 24(14), 11504. https://doi.org/10.3390/ijms241411504

Vancouver

Terrin M, Migliorisi G, Dal Buono A, Gabbiadini R, Mastrorocco E, Quadarella A, et al. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management. International Journal of Molecular Sciences. 2023;24(14):11504. doi:10.3390/ijms241411504

BibTeX
@article{Terrin2023,
  author = {Terrin, Maria and Migliorisi, Giulia and Dal Buono, Arianna and Gabbiadini, Roberto and Mastrorocco, Elisabetta and Quadarella, Alessandro and Repici, Alessandro and Santoro, Armando and Armuzzi, Alessandro},
  title = {Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {14},
  pages = {11504},
  doi = {10.3390/ijms241411504}
}
Kostenlos starten →